Søgning
Søgning på udtrykket 'pseudomonas' giver 21 resultater
Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [1]
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Infection and Immunity
11.03.2025
Infection and Immunity, Ahead of Print.
Infection and Immunity
19.02.2025
Infection and Immunity, Ahead of Print.
Infection
16.02.2025
. Abstract. . Introduction. Non-fermenting Gram-negative bacilli (NFGNB) other than Pseudomonas aeruginosa and Acinetobacter baumannii complex are pathogens of interest due to their ability to cause health-care associated infections and display complex drug resistance phenotypes. However, their clinical and microbiological landscape is still poorly characterized. . . .
Infection
16.02.2025
. Abstract. . Purpose. To determine predictors of mortality among patients with Pseudomonas aeruginosa bacteraemia. . . . Methods. Retrospective study. . . . Setting.
Infection
31.01.2025
…rformed a monocentric retrospective analysis of 361 lung transplantations performed in Homburg, Germany, between 1995 and 2020. All recipients with a main diagnosis of cystic fibrosis (n = 69) were stratified into two groups based on colonization with Pseudomonas aeruginosa in view of MRGN before transplantation: no colonization and colonization without (n = 23) or with (n = 46) resistance to three or four antibiotic groups (3MRGN/4MRGN).
Infection
31.01.2025
. Abstract. . Purpose. Bloodstream infections (BSIs) cause significant morbidity and mortality worldwide. Pseudomonas aeruginosa is an important microorganism in BSIs. The aim of this study was to analyze recent trends in the incidence and resistance rates of P. aeruginosa BSIs in Switzerland and its different linguistic regions. . . . Methods.
Infection
24.01.2025
. Abstract. . Purpose. Bloodstream infections caused by Pseudomonas aeruginosa (PABSI) in hematological patients are associated with high morbidity and mortality. We investigated the epidemiology, risk factors, and outcomes of PABSI at our center. . . . Methods. All adult hematological patients with PABSI between January 2013 and July 2023 were included.
Infection
24.01.2025
BMC Infectious Diseases
3.01.2025
. Abstract. . Background. Pseudomonas aeruginosa is one of the leading causes of nosocomial infections and the most common multidrug-resistant pathogen. This study aimed to determine antimicrobial resistance patterns, biofilm-forming capacity, and associated factors of multidrug resistance in P. aeruginosa isolates at two hospitals in Addis Ababa, Ethiopia. . . .
Clinical Microbiology and Infection
31.12.2024
To compile the evidence of sub-groups of patients with Pseudomonas aeruginosa (P. aeruginosa) infection from randomized control trials (RCTs) evaluating different definite antipseudomonal monotherapies for severe P.aeruginosa infection.
BMC Infectious Diseases
29.12.2024
…rulence remains largely unexplored. . . . Methods. Here, we employed an in vitro infection model to investigate the role of Cho in intracellular survival and virulence of Pseudomonas aeruginosa (P. aeruginosa). Additionally, a comprehensive RNA-seq based transcriptomic analysis and various phenotypic assays were performed to elucidate the impacts of Cho on P. aeruginosa. . . .
BMC Infectious Diseases
27.12.2024
. Abstract. . Background. The World Health Organization (WHO) has identified carbapenem-resistant Pseudomonas aeruginosa (CRPA) as one of the three critical priority pathogens. There is scarce literature evaluating the treatment outcomes in patients with CRPA infections treated with traditional non-carbapenem β-lactam (NCBL) agents.
PLoS One Infectious Diseases
17.12.2024
by Yutong Wu, Yuqi Shi, Xiaohui Liang . Pseudomonas aeruginosa is an opportunistic human pathogen causing various severe infections. Understanding genetic mechanisms of its metabolic versatility aids in developing novel antibacterial drugs and therapeutic strategies to address multidrug-resistant P. aeruginosa infections. The metabolism of nucleotides and amino acids contributes to the cycle of two key biological macromolecules in the genetic central dogma.
Lancet Infectious Diseases
17.12.2024
Treatment with ceftolozane–tazobactam resulted in higher rates of clinical success compared with ceftazidime–avibactam for invasive infections due to multidrug-resistant P aeruginosa. Differences were driven by improved response rates for patients with pneumonia who were treated with ceftolozane–tazobactam. There were no significant differences between study groups with respect to all-cause mortality; treatment-emergent resistance was common with both agents.
Infection and Immunity
14.12.2024
Infection and Immunity, Ahead of Print.
Infection
4.12.2024
. Abstract. . Purpose. The emergence of multidrug-resistant P. aeruginosa isolates poses a challenge to healthcare systems worldwide. Rising numbers in deaths, duration of hospitalization as well as failing treatments prove the hazards posed by these pathogens. This and the lack of promising therapeutic options highlight the urgency of antibiotic drug development.
Virulence
2.12.2024
Volume 15, Issue 1, December 2024 .
Trends in Microbiology
29.11.2024
Pseudomonas fluorescens is a Gram-negative environmental bacterium often studied as a key contributor to plant and soil health. Pan-genome analysis suggests that P. fluorescens is not a single species, but is better described as a species complex (a set of closely related species that are very similar in appearance and traits), within which there are more than 50 species along with many unclassified isolates.
Emerging Infectious Diseases
26.11.2024
Research Letter - Canine Multidrug-Resistant Pseudomonas aeruginosa Cases Linked to Human Artificial Tears-Related Outbreak
PLoS One Infectious Diseases
20.11.2024
by Suvadee Supreeyasakon, Jantima Traipattanakul, Jatapat Hemapanpairoa, Piraporn Juntanawiwat, Wichai Santimaleeworagun . Pseudomonas aeruginosa associated with hospital-acquired infection is often resistant to various antibiotics and is associated with high mortality worldwide. The appropriate treatment of Pseudomonas aeruginosa resistant to carbapenems but susceptible to traditional antipseudomonal non-carbapenem β-lactam agents (Car-R/NonCar-S P. aeruginosa) remains unclear.
Aktuelle smitsomme sygdomme [1]
Aktuelle smitsomme sygdomme [1]
Eurosurveillance latest updates
8.03.2025
…ealth inequalities surrounding bacteraemia in England, to identify high-risk population groups and areas of intervention. . . Methods. We retrospectively analysed English surveillance data between 2018 and 2022 for Escherichia coli, Klebsiella species, Pseudomonas aeruginosa, and both meticillin-sensitive and resistant Staphylococcus aureus (MSSA, MRSA) bacteraemia.